Literature DB >> 3389848

The relationship of basal cell carcinomas and squamous cell carcinomas to solar keratoses.

R Marks1, G Rennie, T Selwood.   

Abstract

Six thousand four hundred sixteen people aged 40 years and over from three different locations in Victoria (Australia) were examined on the hands, forearms, head, and neck for the presence of solar keratoses and basal (BCCs) and squamous cell carcinomas (SCCs). Analysis of the relationship between these tumors revealed that the factors which predicted the likelihood of developing a solar keratosis were essentially the same as those that predicted the likelihood of developing a BCC and/or an SCC. These were age, sex, years of residence in Australia, indoor or outdoor occupation, tanning ability, propensity to sunburn, and location of residence. The presence of a coexisting solar keratosis was necessary for the development of an SCC in contrast to the development of a BCC. The findings suggest that unlike BCCs, the majority of SCCs in light-exposed areas may arise from preexisting solar keratoses. Whereas the prevalence of BCCs and SCCs was relatively constant in the three locations, the prevalence of solar keratoses differed markedly in direct relation to the degree of isolation. This suggests that solar keratoses are a more sensitive indicator of sunlight exposure than invasive carcinoma.

Entities:  

Mesh:

Year:  1988        PMID: 3389848

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  10 in total

1.  Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.

Authors:  Abel Torres; Leslie Storey; Makala Anders; Richard L Miller; Barbara J Bulbulian; Jizhong Jin; Shalini Raghavan; James Lee; Herbert B Slade; Woubalem Birmachu
Journal:  J Transl Med       Date:  2007-01-26       Impact factor: 5.531

Review 2.  Actinic keratoses. Differential diagnosis and treatment.

Authors:  J W Barnaby; A R Styles; C J Cockerell
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

3.  Predictors for cutaneous basal- and squamous-cell carcinoma among actinically damaged adults.

Authors:  J A Foote; R B Harris; A R Giuliano; D J Roe; T E Moon; B Cartmel; D S Alberts
Journal:  Int J Cancer       Date:  2001-01-20       Impact factor: 7.396

Review 4.  Prevention of non-melanoma skin cancer.

Authors:  S P Stratton
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

5.  Prevention, early detection and team management of skin cancer in primary care: contribution to The health of the nation objectives.

Authors:  A Jackson
Journal:  Br J Gen Pract       Date:  1995-02       Impact factor: 5.386

Review 6.  UV and pigmentation: molecular mechanisms and social controversies.

Authors:  T Thanh-Nga Tran; Joshua Schulman; David E Fisher
Journal:  Pigment Cell Melanoma Res       Date:  2008-10       Impact factor: 4.693

Review 7.  Current status of pharmacogenomics testing for anti-tumor drug therapies: approaches to non-melanoma skin cancer.

Authors:  Rebecca Grealy; Lyn R Griffiths
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

8.  Risk factors for keratinocyte skin cancer in patients diagnosed with melanoma, a large retrospective study.

Authors:  Pablo Espinosa; Ruth M Pfeiffer; Zaida García-Casado; Celia Requena; Maria Teresa Landi; Rajiv Kumar; Eduardo Nagore
Journal:  Eur J Cancer       Date:  2015-12-17       Impact factor: 9.162

9.  Predicting keratinocyte carcinoma in patients with actinic keratosis: development and internal validation of a multivariable risk-prediction model.

Authors:  S Tokez; M Alblas; T Nijsten; L M Pardo; M Wakkee
Journal:  Br J Dermatol       Date:  2020-02-26       Impact factor: 9.302

10.  Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.

Authors:  Athina Angelopoulou; Nikos Alexandris; Evangelia Konstantinou; Konstantinos Mesiakaris; Charilaos Zanidis; Konstantinos Farsalinos; Konstantinos Poulas
Journal:  Environ Res       Date:  2020-06-23       Impact factor: 6.498

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.